Large prospective clinical trials consistently indicate that CDK4/6 inhibitors, in combination with ET, significantly prolong the duration of progression-free survival (PFS) for HR+, HER2-metastatic BC (MBC) (8–13). This evidence concerns the gene ERBB2 and breast cancer.